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of these patients receiving 3-line therapy differed significantly in Moscow and St. 
Petersburg, as compared with other regions. ConClusions: Obtained clinical and 
epidemiological data made it possible to fill in the model of management of patients 
with breast cancer in particular regions of Russia.
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objeCtives: Breast cancer is a leading cause of oncological death among Portuguese 
women but a decline in age-standardized mortality rates is well documented and 
due to an increasing frequency of early diagnosis (more than 85% of the women 
aged 45-69 years, underwent a screening mammography according to the most 
recent national health survey) and access to more efficient treatments, including 
adjuvant and neoadjuvant chemotherapy. However, certain tumor characteristics, 
such as Human epidermal growth factor receptor 2 (HER2) -positive breast cancer, 
are associated with poor prognosis for patients with both early and metastatic 
breast cancer. Methods: Previous studies showed that trastuzumab was expected 
to prevent metastases in about 700 women during 10 years if used in early breast 
cancer, in Portugal. T-DM1 significantly prolonged progression-free (3 m) and over-
all survival (6 m) compared to lapatinib plus capecitabine in patients with HER2-
positive advanced breast cancer previously treated with trastuzumab and a taxane. 
Also, the combination of pertuzumab, trastuzumab, docetaxel, as compared with 
placebo, trastuzumab, docetaxel, when used as first-line treatment for HER2-positive 
metastatic breast cancer, significantly prolonged progression-free survival. These 
trials data and population epidemiological information is used to fit predictive 
models adjusting for available confounders. Results: Although high quality data 
on patients with HER2-positive metastatic disease regarding age and other potential 
health differences is lacking, particularly in Portugal, we modeled population meas-
ures of frequency and applied data describing the clinical epidemiology of meta-
static breast cancer to anticipate the potential impact of these treatment options on 
the quality and the quantity of life of affected individuals, taking into consideration 
the period 2014-24. Additionally, by contrasting the available alternatives, we will 
present an estimation of the averted expenses regarding treatment options for the 
same period. ConClusions: The study provides information on health gains and 
evidence for decision making.
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objeCtives: The latest available published oncology national data from the Slovak 
Republic (SR) are for year 2008. The objective of this analysis was to evaluate long-
term national trends of breast cancer (BC) incidence, mortality, clinical stages and 
prevalence to obtain more actual data for the purpose of cost-of-illness studies 
and budget impact analysis in the SR. Methods: Time-trends of national data 
on incidence, mortality, clinical stages and prevalence of BC in 1978-2008 were 
analyzed by using joint-point regression (Version 4.0.4. - May 2013). The data were 
predicted to the current year 2014. The trends are presented with a correspond-
ing 95% Confidence Intervals (CI) and p-value with null hypothesis being constant 
with time. Results: In 2008, BC age-standardized incidence in the SR represented 
59.8/100,000 females (n= 2.639 cases, mean age of women= 61.9 y.), in 1978-2008 the 
incidence was increasing continuously with annual percentage change (APC) of 2.2% 
(95% CI= 2.1-2.3, p< 0.0001), estimation for 2014 is 63.8/100,000 (n= 3.081). Mortality 
in 2008 represented 15.2/100,000 (n= 751) with four join-points and decreasing trend 
from 2001 by APC -3.6% (95% CI= -7.2-0.1, p< 0.04), estimation for 2014 is 14.0/100,000 
(n= 820). National prevalence in 1978-2008 represents 22.118 cases, for 2014 estimate 
is 29.012. According to the national data, in 2014 we estimate 32.6% of patients 
diagnosed in the 1st clinical stage, 36.2% in the 2nd, 16.4% in the 3rd, 7.0% in the 
4th and 7.8% in the undefined clinical stage. The number of cases diagnosed in the 
1st clinical stage is increasing during the time. Despite the observed increase in the 
values of BC incidence, the decrease in mortality has manifested itself in recent 
years. ConClusions: Actual data on incidence, mortality, prevalence and clinical 
stages of BC in the SR can be used as the source for setting the size of population 
in cost-of-illness studies and budget impact analysis.
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objeCtives: Stage IB cutaneous melanomas are characterized by a low risk for 
recurrence and a high survival. However, empirical evidence on recurrence patterns 
and survival subsequent to recurrence is limited. We investigated overall survival 
(OS) and recurrence patterns, and assessed whether the time-to-recurrence was 
associated with prognostic factors. Methods: The Dutch Comprehensive Cancer 
Centers registry was used to identify patients diagnosed with stage IB melanoma 
between January 2003 and December 2011 in six Dutch hospitals including two 
academic and four general hospitals (n= 971). Data were retrospectively collected 
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objeCtives: Treatment of multiple myeloma (MM) consists of a consecutive appli-
cation of various treatment modalities. The optimal sequence of different treat-
ment combinations is unclear. There is a need for the establishment of an analytic 
framework comparing overall survival (OS) of different treatment sequences in MM. 
This analysis contains the first attempt to create such a framework. Methods: 
We performed a systematic literature review (SLR) on treatments compared in 
randomized controlled trials in newly diagnosed and relapsed MM patients. The 
following treatment/combinations were considered; melphalan/prednisone (MP), 
dexamethasone (D), thalidomide (T), bortezomib (V) and lenalidomide (R). Response, 
time to next treatment (TTNT) and OS data were extracted. Response rates were 
derived and pooled for each treatment and treatment line using ordered logistic 
network meta-analysis. The pooled estimates were combined in a Markov model 
framework with treatment switch and mortality transition probabilities to predict 
OS. Seventeen sequences were tested, one starting with MPR and four for each 
starting with MP, MPT, MPV and MPVT. Results: Estimations on the basis of the 
Markov model showed that median OS varied between 40-43,42-45,43,44-47 and 
46-49 months for sequences starting with MP, MPT, MPR, MPV and MPVT, respec-
tively. ConClusions: This study shows a first attempt to build an analytic frame-
work comparing OS of treatment sequences in MM. The absolute results should be 
interpreted with caution, as MM is a heterogeneous disease and the model does 
not yet capture all subtleties related to sequential treatment in clinical practice. 
However, face validity of these first results seem promising and warrant further 
development of this analytic framework.
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objeCtives: The effect of having a positive anaplastic lymphoma receptor tyrosine 
kinase (ALK) mutation on the burden of disease in Stage IV non-small cell lung 
cancer (NSCLC) is unknown. This study compared the burden of disease in ALK 
positive Stage IV NSCLC with ALK negative Stage IV NSCLC. Methods: Burden 
of disease by ALK mutation status was evaluated in Egypt, Russia, and the United 
Arab Emirates (UAE) using disability adjusted life years (DALYs). A burden of disease 
model was developed in line with World Health Organisation (WHO) guidelines. 
Epidemiological data were collected by a survey disseminated during interviews in 
at least three centres per country. Disability weights were obtained from a Dutch 
study. Discounting, age-weighting and life expectancies were based on the WHO 
reference case. Sensitivity analyses were conducted to test the level of uncertainty 
in the model results. Results: Total DALYs across the countries were lower in ALK 
positive disease compared to ALK negative disease (833 vs. 2611). On a per country 
basis, total DALYs were higher in ALK positive disease compared to ALK negative 
disease for Egypt (22 vs. 11) and UAE (229 vs. 219) but lower for Russia (582 vs. 
2381). DALYs per incident case of the disease were consistently higher across the 
countries in ALK positive disease compared to ALK negative disease (Egypt: 11.24 
vs. 10.85; Russia: 9.38 vs. 4.97; UAE: 15.29 vs. 7.82). Results were sensitive to changes 
in discounting, age-weighting, deaths, and incidences. ConClusions: The study 
would suggest that the greatest burden of disease lies in the population with ALK 
negative Stage IV NSCLC compared to ALK positive Stage IV NSCLC, although this 
finding varied between countries. However, it was consistently found that a single 
patient with Stage IV NSCLC will have a greater burden of disease if their ALK 
mutation test is positive.
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objeCtives: In Russia, breast cancer (BC) took first place in the structure of cancer 
incidence and mortality in the female population. Modern therapeutic approaches 
advanced breast cancer (ABC) can achieve clinically significant regression of symp-
toms, prolong life and improve its quality. Aim of this study was to conduct clinical 
and epidemiological analysis of reference postmenopausal patients with hormone- 
(HR+), HER2-ABC in Russia. Methods: Survey of experts from different regions 
of Russia. The questionnaire included the following questions: the proportion of 
patients with different types of breast cancer; drugs and modes of their appoint-
ment as the first, second and third-line treatment of patients postmenopausal 
HR+, HER2-ABC; hospitalization rate per year; laboratory and instrumental methods 
of research, consulting, adverse events with the use of drugs in the treatment of 
patients and their drug regimes correction. Results: From 13 regions of Russia 7 
experts refused to provide information on the questionnaire, which may indicate 
a reluctance to disclose information on the epidemiology and the tactics of the 
disease. Data were obtained from the regions - Moscow, Saint Petersburg, Republic 
of Khakassia, Omsk region, Primorsky Krai, Krasnoyarsk Krai. Share of the growth 
of new breast cancer patients is 10,5-29,6% (median 13.4%) per year. Number of 
patients with ABC from patients with breast cancer is 9,2-53% (median-30%). On 
average, 70% of patients with ABC are in menopause. Number of patients with HR+, 
ER2-ABC at the end of 2013 amounted to Moscow-1772, St. Petersburg-492, Republic 
of Khakassia-188, Omsk region-344, Primorsky Krai-358, Krasnoyarsk Krai-3471. The 
average frequency of hospitalizations in these patients is 6 times a year. Proportion 
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tion. Methods: IMS Disease Analyzer™ (DA) database was used, focusing on 
patients with or without diabetes in general practice in France. The analysis was 
performed retrospectively from 2001 to 2013. The Hazard Ratios (HR; Cox regres-
sion) for the risk of cancer in diabetic versus non-diabetic patients were adjusted 
for demographic and clinical variables. IMS Oncology Analyzer™ (OA) database was 
also used to describe the cancer patient profile in 2013. Results: Overall 3.1% of 
patients in DA are diabetic. 75,104 patients were diagnosed with type-2 Diabetes 
Mellitus (T2DM). This population was matched to a control group in terms of age 
(60±15 years) and gender (male: 52%). The overall risk of cancer was lower in T2DM 
patients than in patients without diabetes (HR: 0.81; CI: 0.76 to 0.85). Those patients 
were less likely to develop breast, prostate, lung cancer or non-hodgkin lymphoma. 
Nevertheless, their risk was significantly higher regarding liver cancer (HR: 1.99; CI: 
1.46 to 2.72), pancreatic cancer (HR: 2.13; CI: 1.51 to 3.00) and endometrial cancer 
(HR: 1.25; CI: 1.01 to 1.55). No significant increase in risk was observed in colorectal, 
stomach, kidney, thyroid, urinary bladder, gall bladder and oesophageal cancer. 
OA showed a higher proportion of diabetic patients among the cancer population 
(14.6%, n= 10,621). Consistently, this rate was even higher in patients diagnosed 
with pancreatic (28.7%, n= 362), liver (27.0%, n= 256) and endometrial cancer (21.7%, 
n= 161). ConClusions: This retrospective analysis showed that T2DM may increase 
the risk of certain cancer types but seems to prevent from some others. Further 
research is required to evaluate the factors involving the diabetes-cancer correla-
tions, such as the anti-diabetic drugs.
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objeCtives: To forecast the number of advanced melanoma (AM) patients (Stage 
III unresectable and Stage IV) newly initiating treatment over 5 years (2014-2018) 
by line of therapy and clinical/tumor characteristics including BRAF/PD-L1 muta-
tions status and rate of brain metastases. Methods: A patient count model was 
developed to forecast the AM population using historical rate data (1991-2012) and 
other population parameters including incidence rate annual percent change, stage 
at diagnosis, rates of disease progression and survival obtained through a compre-
hensive literature review and hand-search of cancer registry websites. Analysis of a 
cross-sectional sample (Ipsos Global Oncology Monitor) of 1,297 patients in the EU-5 
was used to address any clinical data gaps. The model was validated by compar-
ing projected 5-year prevalence rates to GLOBOCAN 2012 estimates. Results: The 
model-projected number (rounded to nearest 100) of incident melanoma cases for 
2014 was: Germany= 23,100; UK= 18,900; France= 12,400; Italy= 12,000; Spain= 5,800. 
Of incident cases, 11.3%-13.0% were treatment eligible AM. Incidence rates increases 
of 1.7-7.8% per year were applied based on historical trends. Analysis of IPSOS data 
and review of the literature showed BRAF and PD-L1 prevalence rates of 45.4%-56.2% 
and 15.9%-16.7%, in AM patients, respectively. Literature-derived, brain metastasis 
prevalence ranged from 15.9-36.0% in Stage IV patients. Considering case progres-
sion, resection and adjuvant treatment rates, the forecasted number of AM patients 
eligible for 1stand 2nd line treatment in 2018 is, respectively: Germany= 3,700 and 
1,700; UK= 3,100 and 1,400 France= 1,900 and 500; Italy= 1,800 and 1,000; Spain= 1,100 
and 400, representing approximately 10.8-12.0% of incident cases. ConClusions: 
While melanoma incidence is projected to increase over the next 5 years the 
majority of incident cases will be diagnosed in earlier disease stages. Under these 
assumptions, the largest proportion of the incident melanoma population that is 
AM patients initiating treatment is expected to be 12% in 2018, a slight decline 
from 13% in 2014.
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objeCtives: The objective of this study is to develop and validate a conditional 
logistic regression model for the prediction of locoregional recurrence (LRR) of 
breast cancer. To make a translation to clinical practice a web based nomogram 
was made. Methods: Women first diagnosed with early breast cancer (without 
distant metastasis or ingrowth in the chest wall or skin) between 2003-2006 were 
selected from the Netherlands Cancer Registry (n= 39,929). Risk factors for LRRs 
within five year of the primary treatment were determined using logistic regres-
sion. Risks were determined per year, conditional on not being diagnosed with 
recurrence in the previous year. The presence of interaction and collinearity in 
the nomogram was assessed, as well as the discrimination by means of the area 
under the ROC curve and calibration by the Hosmer-Lemeshow goodness-of-fit test 
in deciles. Data on primary tumours diagnosed between 2007-2008 from a selec-
tion of Dutch hospitals was used for external validation of the performance of 
the nomogram (n= 13,792). Results: The final model included the variables grade, 
size, multifocality, and nodal involvement of the primary tumour, type of surgery, 
and whether patients were treated with radio-, chemo- or hormone therapy. The 
modelling group showed an area under the ROC curve of 0.82,0. 74,0. 67,0. 70 and 
0.60 respectively per subsequent year after primary treatment. The calibration was 
sufficient. All effects in the validation group were in the same direction, and the 
estimates in the validation group did not differ significantly from the modelling 
group. ConClusions: This validated nomogram can be used as an instrument to 
aid clinical decision-making and to identify patients with a high risk of breast cancer 
recurrence who might benefit from a more intensive follow-up after breast cancer.
using electronic hospital records. Survival was assessed using the Kaplan-Meier 
estimator. Recurrence patterns were investigated by type of first recurrence and 
time-to-recurrence. A multivariate cox regression was used to analyze whether 
time-to-recurrence was associated with gender, age and tumor thickness. Emigrated 
patients (n= 10) and patients with an unknown recurrence status (n= 144) were 
excluded. Results: Of all 817 patients, 111 patients (13.6%) experienced disease 
progression (median follow-up: 5.5 years). Patients who developed a recurrence had 
a lower survival compared to patients who did not developed a recurrence (median 
OS: 9.4 years versus median has not yet been reached; 5-year survival rate: 69.9% 
versus 96.6%; p< 0.001). The most frequent type of first recurrence was lymphatic 
(36.9%), followed by distant (22.5%), local (21.6%) and intralymphatic (9.9%), respec-
tively. The median time-to-recurrence has not yet been reached; however, in case of 
a recurrence, the median time-to-recurrence was 2.5 years (minimum: 0.01 years; 
maximum: 9.8 years). The time-to-recurrence was not statistically significantly asso-
ciated with gender (HR= 0.81; p= 0.29), age (HR= 1.01; p= 0.38) and tumor thickness 
(HR= 1.03; p= 0.76). ConClusions: Long-term surveillance of stage IB melanomas 
is of utmost importance, because survival subsequent to recurrence is much lower 
than expected. The risk of developing a recurrence was substantial; however, the 
time-to-recurrence was not associated with gender, age and tumor thickness.
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objeCtives: The objective of this study was to evaluate both the incidence 
of metastatic Castrate Resistant Prostate Cancer (mCRPC) and the number of 
mCRPC patients who receive specific mCRPC treatments (mCRPCTT): chemo-
therapy and second generation Hormone Therapies (ADT manipulations were 
not included). Methods: This study was conducted in 8 European countries and 
Australia The incidence of mCRPC patients was assessed using several sources: 
national cancer registries, a literature review and an ad-hoc chart review where 
292 oncologists, 76 onco-radiotherapists and 357 urologists reported information 
about 4171 prostate cancer patients. Of these, 2401 had metastatic castrate resistant 
disease. Patient characteristics and treatments received were assessed and reported 
separately by country. Results: Across all 9 countries, 76 200 new patients were 
diagnosed mCRPC over the past year. Of these patients, 35% (26 400 patients) went 
to supportive care without receiving any mCRPC TT while 65% (49 800 patients) 
received a 1L mCRPCTT. Prior to receiving any 1L mCRPCTT, 43% of patients had ADT 
manipulations during a short transitional period (median duration = 1 month). Of 
the 49 800 patients who received a 1L mCRPCTT, 59% (29 250) went to a 2L mCRPCTT, 
15% deceased during or just after the 1L TT and 26% went on to receive supportive 
care only. Of the 29 250 patients who received a 2L mCRPCTT, 46% (13 500) went to 
a 3L mCRPCTT. ConClusions: Our methodology enabled us to assess incidence 
figures and the volume of mCRPC patients who receive specific mCRPCTT: over 
one-third of mCRPC patients did not receive any mCRPCTT. Among the 65% who 
received a 1L TT, 59% receive a 2L mCRPCTT.
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objeCtives: Explore differences/similarities in epidemiology and drug treatment 
of metastatic breast cancer (MBC) in EU5. Methods: All data was derived from the 
Kantar Health CancerMPact database, sources for which include country specific 
cancer registries, published scientific studies and proprietary physician surveys 
comprising 85 doctors seeing 9,255 patients per month. Age and gender specific 
incidence rates, annual stage specific progression rates and annual stage specific 
survival rates are used to calculate total number of surviving patients at a specific 
stage up to 10 years after diagnosis. Results: Prevalence of BC ranged between 
41-73 per 100K population across EU-5. Among BC patients, prevalence of MBC was 
similar: 8% (UK, Italy) to 10% (Germany, France, Spain). Overall 62% of MBC patients 
were diagnosed with HER2-negative disease (56% Germany-70% France). Among 
these patients 35-40% had active disease and were treated with chemotherapy. 
Patients with triple negative disease had had fewer lines of treatment than did 
not triple negative. Patients who are HER2-negative generally receive between two 
and three lines of chemo therapy on average. Second line chemotherapy regimens 
varied. Capecitabine was the most common therapy (mono and combination) in 
all countries ranging from 36% (UK) to 40% (Germany). 2nd and 3rdmost common 
therapies were vinorelbine (23%-26%) and paclitaxel (20%-23%) in Germany, Italy 
and Spain vs. docetaxel (18%-34%) and paclitaxel (11%-19%) in UK and France. 
In third line, the most commonly used agents were capecitabine (16%-44%) and 
vinorelbine (18%-26%). Eribulin was used in second line (3%-6%) and third line (11%-
19%) in all countries except for Spain. ConClusions: Capecitabine is the most 
utilized chemotherapeutic agent in the second and third lines chemotherapy in 
Western Europe for HER2-negative patients. A variety of other regimens, primarily 
monotherapies, may also be used in later lines, including vinorelbine, gemcitabine, 
eribulin, and docetaxel.
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objeCtives: Several studies suggest that diabetes carries an increased risk for 
a number of different cancer types. The aim of this study was to investigate the 
incidence of 14 different cancer types in the diabetic and non-diabetic popula-
